Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04545762
Recruitment Status : Recruiting
First Posted : September 11, 2020
Last Update Posted : September 22, 2020
Sponsor:
Collaborator:
University of California, Davis
Information provided by (Responsible Party):
C. Babis Andreadis, University of California, San Francisco

Brief Summary:
This study will assess safety and feasibility of infusing genetically modified autologous T cells transduced to express a chimeric antigen receptor targeting the B cell surface antigen Cluster of Differentiation 19 (CD19)

Condition or disease Intervention/treatment Phase
Refractory Non-Hodgkin Lymphoma Burkitt Lymphoma Mantle Cell Lymphoma Follicular Lymphoma Lymphoplasmacytic Lymphoma Primary Mediastinal Large B Cell Lymphoma Diffuse Large B Cell Lymphoma Small Lymphocytic Lymphoma Transformed Lymphoma Drug: Fludarabine Drug: Cyclophosphamide Biological: anti-CD19 CAR-T cells Phase 1

Detailed Description:

This is an open-label, pilot, phase 1 study to determine the safety profile of anti-CD19 CAR-T cell infusion in participants with R/R B-cell NHL. The dose-finding cohorts in this study will evaluate and define the safe dose of anti-CD19 CAR-T cells. Using a "3+3" design, participants will be enrolled sequentially to each dose level. A dose expansion will then occur at the maximum tolerated dose (MTD) and dose levels that have not exceeded the MTD.

Up to 36 participants will be enrolled and treated. Each subject will provide consent and be evaluated for study eligibility. Eligible subjects will undergo apheresis with collection of autologous peripheral blood mononuclear cells that will be used to generate CAR-T cells. The CAR T cells will be produced using the Miltenyi Prodigy and an FDA compliant Lentigen CD19 targeted lentiviral vector. After successful generation of the anti-CD19 CAR-T cells (drug product (DP)), subjects will undergo lymphodepleting chemotherapy with fludarabine and cyclophosphamide followed by 2-5 days of rest. A single infusion of anti-CD19 CAR-T cells at the starting dose of 5 x 105 cells/kg will be given on Day=0. Following treatment with DP, subjects will be followed on this study for 12 months for safety, disease status, and survival. For long term follow-up, participants will be followed for 15 years.

PRIMARY OBJECTIVES

  1. To evaluate the safety of administering chimeric antigen receptor T cells targeting CD-19 to patients with relapsed or refractory CD19+ B-cell nonHodgkin lymphoma (NHL).
  2. To determine the recommended phase 2 dose (RP2D) for this cellular therapy.

SECONDARY OBJECTIVES

  1. To assess the safety and toxicity of cell collection and infusion of CAR-T cells targeting CD19 in patients with relapsed or refractory CD19+ B cell NHL.
  2. To describe the efficacy of chimeric antigen receptor T cells targeting CD-19 in patients with relapsed or refractory CD19+ B cell NHL.
  3. To evaluate the feasibility of CD19 CAR T cell manufacturing for patients with relapsed or refractory CD19+ B cell NHL of local manufacturing and ability to produce adequate quantities of vector positive T-cells

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 36 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Clinical Trial of Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Actual Study Start Date : September 11, 2020
Estimated Primary Completion Date : October 31, 2023
Estimated Study Completion Date : October 31, 2023


Arm Intervention/treatment
Experimental: Treatment Regimen

Apheresis (1 day): Autologous lymphocytes/ mononuclear cell collection will be collected through standard apheresis procedures as per University of California, San Francisco (UCSF) institutional practices

CAR-T cell manufacturing (estimated ~13-14 days)

Lymphodepleting chemotherapy: 3 days of immunosuppressive chemotherapy. Cyclophosphamide given at a dose of 300 mg/m2/IV and fludarabine given at 30 mg/m2 /IV on days -5, -4, and -3.

CAR-T cell infusion (1 day): The infusion of CAR-T cells targeting CD19 will occur over 5-30 minutes.

Drug: Fludarabine
Given intravenously (IV)
Other Names:
  • Fludarabine 30mg/m2
  • Fludara

Drug: Cyclophosphamide
Given intravenously (IV)
Other Names:
  • Cyclophosphamide 300mg/m2
  • Cytoxan
  • Endoxan
  • Neosar
  • Procytox
  • Revimmune
  • Cycloblastin

Biological: anti-CD19 CAR-T cells
Single infusion




Primary Outcome Measures :
  1. Proportion of participants with treatment-emergent adverse events (AEs) [ Time Frame: From initiation of study treatment to 12 months following CAR-T infusion, approximately 15 months ]
    All subjects enrolled in this phase I study who actually received study drug (anti-CD19 CAR-T infusion) will be included in the analysis. Proportion of participants with treatment-emergent adverse events of CAR-T in B-cell NHL, as graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 5.0), revised Cytokine Release Syndrome (CRS) grading criteria, and American Society for Transplantation and Cellular Therapy (ASTCT) immune effector cell (IEC) -associated neurotoxicity syndrome (ICANS) Consensus Grading for Adults (for neurotoxicity grading).

  2. Proportion of participants who experience a dose-limiting toxicity (DLT) [ Time Frame: From initiation of study treatment to 30 days following CAR-T infusion ]
    A DLT includes those AEs graded according to CTCAE version 5.0, with the exceptions of CRS and neurotoxicity, which are graded using CRS and ICANS criteria. DLTs must 1) be suspected to be secondary to CAR-T cell infusion, 2) occur during the first 30 days after infusion and 3) meet the following criteria: 1. Grade 3 or 4 non-hematologic toxicities of any duration, with the following exceptions: Grade 3 laboratory abnormalities without associated symptomatology or clinical consequence that resolve in < 7 days; AEs associated with Grade <= 2 CRS; Toxicities associated with Grade 3 CRS (except cardiac or pulmonary organ toxicity) that improves to grade <= 2 within 3 days of intervention; isolated renal or hepatic grade 3 organ toxicity that does not resolve within 7 days; Laboratory abnormalities compatible with tumor lysis syndrome; Grade 4 hematological toxicity that persists at grade >= 3 despite maximum supportive care for >21 days.


Secondary Outcome Measures :
  1. Proportion of participants with delayed infusion due to study-related adverse events [ Time Frame: From T-cell collection to end of infusion, approximately 18 days ]
    The proportion of participants who have their infusion delayed due to and AE will be reported.

  2. Table of adverse events related to collection and infusion of CAR-T cells [ Time Frame: From T-cell collection to end of infusion, approximately 18 days ]
    Frequency and severity for each adverse event of collection and infusion of CAR-T cells targeting CD19 in participants with relapsed B cell Non-Hodgkins Lymphoma

  3. Response rates over time [ Time Frame: From initiation of study treatment to 12 months after getting CAR-T infusion, approximately 15 months ]
    Response rates will be categorized by overall, partial, and complete and will be reported as proportions at different time points across the study

  4. Best response rates [ Time Frame: From initiation of study treatment to 12 months after getting CAR-T infusion, approximately 15 months ]
    Best overall, best partial, and best complete response rates will be calculated for the study overall. These will be reported cumulatively across the study population and across disease subtypes in a table format. Any comparisons will be hypothesis-generating and will be performed using Fisher's exact or the Chi-square test.

  5. Duration of response [ Time Frame: From initiation of study treatment to 12 months after getting CAR-T infusion, approximately 15 months ]
    This is measured, only in responders, from the documented beginning of response (CR or PR) to the time of relapse

  6. Progression-free survival (PFS) [ Time Frame: From initiation of study treatment to 12 months after getting CAR-T infusion, approximately 15 months ]
    PFS is defined as the time from entry onto study until lymphoma progression or death from any cause at 12 months after receiving CAR-T infusion.

  7. Overall Survival [ Time Frame: Up to 15 years ]
    Defined as the time from entry onto study until death from any cause

  8. Proportion of subjects for whom CD19 CAR T-cell therapy is manufactured [ Time Frame: From initiation of CD19 CAR T-cell manufacturing to end of infusion, approximately 18 days ]
    Feasibility will be assessed by the proportion of subjects for whom the ability to produce adequate quantities of vector.

  9. Proportion of participants who complete study treatment [ Time Frame: From initiation of CD19 CAR T-cell manufacturing to end of infusion, approximately 18 days ]
    Feasibility will be assessed by the proportion of subjects who complete the study regimen



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients must have a diagnosis of relapsed or refractory B-cell NHL:

    • DLBCL, Mantle Cell, Follicular Lymphoma, Lymphoplasmacytic lymphoma, Small Lymphocytic Lymphoma, Primary Mediastinal B-Cell Lymphoma, Burkitt Lymphoma, transformed lymphoma.

      • Subjects with small lymphocytic lymphoma (SLL) must have progressed after at least 2 prior therapies and prior treatment with or intolerance of both ibrutinib and venetoclax.
      • Subjects with DLBCL, primary mediastinal B- Cell lymphoma, Burkitt lymphoma and transformed lymphoma must have relapsed or failed to respond to >= 2 prior lines of multiagent chemoimmunotherapy with prior exposure to both an anti-CD20 antibody agent and an anthracycline.
      • Subjects with indolent lymphomas (follicular lymphoma and lymphoplasmacytic lymphoma) must have relapsed after or been refractory to >=2 prior lines of multi-agent chemoimmunotherapy including prior exposure to rituximab and at least 2 other chemotherapy agents.
      • For subjects with Mantle cell lymphoma, previous lines of therapy may include multiagent chemotherapy including alkylating agent or anthracycline and anti CD20 antibody therapy and Bruton's tyrosine kinase (BTK) inhibitor therapy.
    • Positron Emission Tomography (PET) -positive disease according to "Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification"
    • At least one of the following:

      • Primary refractory or early relapse (first remission < 12 months) and not eligible for stem cell transplant
      • Relapsed or refractory disease after two or more lines of systemic therapy
    • No significant circulating disease, defined as an elevated total lymphocyte count above the ULN due to the presence of malignant cells.
  2. CD19 positive by either immunohistochemistry or flow cytometry analysis on any biopsy. If prior anti-CD19 therapy has been administered, CD19 positivity has to be re-established on the most recent biopsy.
  3. Age >=18 years at the time of consent
  4. Absolute lymphocyte count > 100/ (microliter)
  5. Eastern Cooperative Oncology Group (ECOG) performance status < 2
  6. Adequate organ function, defined as:

    • Adequate bone marrow function for apheresis and lymphodepleting chemotherapy

      • Hemoglobin (Hgb) >8 grams per deciliter (gm/dl) (transfusions allowed)
      • Platelets >50,000/microliter (uL) (transfusions allowed)
      • Absolute Neutrophil Count (ANC) > 500/uL
    • Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) < 3 x institutional upper limit of normal (ULN) and Total bilirubin < 1.5 mg/dl x institutional ULN, except with Gilbert's syndrome
    • Serum Creatinine < 2 x the institutional ULN
    • Adequate cardiac function, defined as left ventricular ejection fraction (LVEF) > 40% as assessed by echocardiogram or multiple uptake gated acquisition (MUGA)
  7. Adequate vascular access for leukapheresis procedure (either peripheral line or surgically placed line).
  8. Women of childbearing potential (defined as all women physiologically capable of becoming pregnant) must have a negative serum or urine pregnancy test AND agree to use highly effective methods of contraception for 1 year after the last dose of antiCD19 CAR-T cells
  9. Males who have partners of childbearing potential must agree to use an effective barrier contraceptive method
  10. Ability to understand a written informed consent document, and the willingness to sign it.

Exclusion Criteria:

  1. Autologous transplant within 6 weeks of planned CAR-T cell infusion
  2. Recipient of prior CAR-T cell therapy targeting CD19 outside of this protocol
  3. Active other malignancy, other than non-melanoma skin cancer, carcinoma in situ (e.g., cervix, bladder, or breast).
  4. HIV seropositivity
  5. Serologic status reflecting active hepatitis B or C infection. Patients that are positive for hepatitis B core antibody, hepatitis B surface antigen (HBsAg), or hepatitis C antibody must have a negative polymerase chain reaction (PCR) prior to enrollment. (PCR positive patients will be excluded.)
  6. Subjects with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, pulmonary abnormalities or psychiatric illness/social situations that would limit compliance with study requirements.
  7. Pregnant or breastfeeding women are excluded from this study because CAR-T cell therapy may be associated with the potential for teratogenic or abortifacient effects. Because there is an unknown, but potential risk for adverse events in nursing infants secondary to treatment of the mother with CAR-T cells, breastfeeding should be discontinued. These potential risks may also apply to other agents used in this study. NOTE: Women of childbearing potential must have a negative serum or urine pregnancy test.
  8. Patients with history of clinically relevant central nervous system (CNS) pathology such as epilepsy, seizure disorders, paresis, aphasia, uncontrolled cerebrovascular disease, severe brain injuries, dementia and Parkinson's disease.
  9. History of autoimmune disease (e.g., rheumatoid arthritis, systemic lupus erythematosus) with requirement of immunosuppressive medication within 6 months.
  10. Body weight <40 kilograms(kg)

Eligibility for Infusion of Investigational Product:

Subjects will undergo a second evaluation of eligibility on day -2 or -1 prior to infusion of antiCD19 CAR-T cell product. This eligibility criterion will include the inclusion and exclusion criteria required for enrollment with the following exceptions and additions

Inclusion criteria exceptions:

  1. Hematologic function parameters will not be included as a pre-infusion eligibility criterion (because lymphodepletive chemotherapy is expected to cause pancytopenia).
  2. Laboratory result abnormalities that are considered not clinically significant by the principal investigator AND are not the result of a demonstrated active infection or an active central nervous system condition.

Exclusion criteria additions:

  1. Use of corticosteroids within 7 days prior to infusion (with exception of agents used for prevention of emesis during lymphodepletive chemotherapy).
  2. Neurologic symptoms suggestive of an active central nervous system condition.
  3. Signs or laboratory markers of active infection or systemic inflammatory response.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04545762


Contacts
Layout table for location contacts
Contact: Julie McCluggage, RN 877-827-3222 cancertrials@ucsf.edu

Locations
Layout table for location information
United States, California
University of California, San Francisco Recruiting
San Francisco, California, United States, 94143
Contact: Julie McCluggage    877-827-3222    cancertrials@ucsf.edu   
Principal Investigator: C. Babis Andreadis, MD         
Sponsors and Collaborators
C. Babis Andreadis
University of California, Davis
Investigators
Layout table for investigator information
Principal Investigator: C. Babis Andreadis, MD University of California, San Francisco
Layout table for additonal information
Responsible Party: C. Babis Andreadis, Principal Investigator, University of California, San Francisco
ClinicalTrials.gov Identifier: NCT04545762    
Other Study ID Numbers: 19703
NCI-2020-06711 ( Registry Identifier: NCI Clinical Trials Reporting Program (CTRP) )
First Posted: September 11, 2020    Key Record Dates
Last Update Posted: September 22, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by C. Babis Andreadis, University of California, San Francisco:
Non-Hodgkin Lymphoma
Anti-CD19 autologous CAR-T cells
Additional relevant MeSH terms:
Layout table for MeSH terms
Burkitt Lymphoma
Lymphoma
Lymphoma, Non-Hodgkin
Lymphoma, B-Cell
Lymphoma, Mantle-Cell
Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoma, Large B-Cell, Diffuse
Waldenstrom Macroglobulinemia
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, B-Cell
Leukemia, Lymphoid
Leukemia
Epstein-Barr Virus Infections
Herpesviridae Infections
DNA Virus Infections
Virus Diseases
Tumor Virus Infections
Neoplasms, Plasma Cell
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders